{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T22:47:27Z","timestamp":1793573247217,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020884","name":"QIAGEN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ijid.2023.03.013","type":"journal-article","created":{"date-parts":[[2023,3,12]],"date-time":"2023-03-12T01:34:36Z","timestamp":1678584876000},"page":"S12-S15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"special_numbering":"S1","title":["Update of drug-resistant tuberculosis treatment guidelines: A turning point"],"prefix":"10.1016","volume":"130","author":[{"given":"Elisa","family":"Vanino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Granozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5638-9260","authenticated-orcid":false,"given":"Onno W.","family":"Akkerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Munoz-Torrico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8184-6291","authenticated-orcid":false,"given":"Fabrizio","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2922-4940","authenticated-orcid":false,"given":"Barbara","family":"Seaworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9424-6551","authenticated-orcid":false,"given":"Simon","family":"Tiberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1005-7532","authenticated-orcid":false,"given":"Marina","family":"Tadolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2023.03.013_bib0001","series-title":"Global tuberculosis report 2022","year":"2022"},{"key":"10.1016\/j.ijid.2023.03.013_bib0002","doi-asserted-by":"crossref","first-page":"590","DOI":"10.5588\/ijtld.22.0263","article-title":"WHO drug-resistant TB guidelines 2022: what is new?","volume":"26","author":"Migliori","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2023.03.013_bib0003","series-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update","year":"2022"},{"key":"10.1016\/j.ijid.2023.03.013_bib0004","series-title":"Rapid communication: key changes to the treatment of drug-resistant tuberculosis","year":"2022"},{"key":"10.1016\/j.ijid.2023.03.013_bib0005","series-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment","year":"2020"},{"key":"10.1016\/j.ijid.2023.03.013_bib0006","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s13063-022-06331-8","volume":"23","author":"Berry","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.ijid.2023.03.013_bib0007","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang'wa","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2023.03.013_bib0008","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1164\/rccm.202107-1779OC","article-title":"An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT Study)","volume":"205","author":"Esmail","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2023.03.013_bib0009","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2023.03.013_bib0010","series-title":"WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update","year":"2022"},{"key":"10.1016\/j.ijid.2023.03.013_bib0011","series-title":"WHO consolidated guidelines on drug resistant tuberculosis treatment","year":"2019"},{"key":"10.1016\/j.ijid.2023.03.013_bib0012","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1183\/09031936.00009509","article-title":"A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis","volume":"34","author":"Migliori","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijid.2023.03.013_bib0013","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/cid\/ciab699","article-title":"Proposed linezolid dosing strategies to minimize adverse events for treatment of extensively drug-resistant tuberculosis","volume":"74","author":"Imperial","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2023.03.013_bib0014","series-title":"WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents","year":"2022"},{"key":"10.1016\/j.ijid.2023.03.013_bib0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000334441","article-title":"QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications","volume":"120","author":"Briasoulis","year":"2011","journal-title":"Cardiology"},{"key":"10.1016\/j.ijid.2023.03.013_bib0016","doi-asserted-by":"crossref","first-page":"00685","DOI":"10.1183\/23120541.00685-2021","article-title":"Safety of prolonged treatment with bedaquiline in programmatic conditions","volume":"8","author":"Zhurkin","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.ijid.2023.03.013_bib0017","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1473-3099(20)30770-2","article-title":"QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial","volume":"21","author":"Dooley","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2023.03.013_bib0018","doi-asserted-by":"crossref","first-page":"986","DOI":"10.5588\/ijtld.22.0264","article-title":"Pediatric delamanid treatment for children with rifampicin-resistant TB","volume":"26","author":"Tyeku","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2023.03.013_bib0019","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.02919-20","article-title":"Bedaquiline drug resistance emergence assessment in multidrug-resistant tuberculosis (MDR-TB): a 5-year prospective in vitro surveillance study of bedaquiline and other second-line drug susceptibility testing in MDR-TB isolates","volume":"60","author":"Kaniga","year":"2022","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijid.2023.03.013_bib0020","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1186\/s12889-021-11427-y","article-title":"Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients","volume":"21","author":"van de Berg","year":"2021","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ijid.2023.03.013_bib0021","doi-asserted-by":"crossref","first-page":"419","DOI":"10.5588\/ijtld.21.0146","article-title":"Shortening MDR-TB treatment: is treating more patients with fewer drugs better?","volume":"25","author":"Akkerman","year":"2021","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971223000899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971223000899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T12:35:31Z","timestamp":1746362131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971223000899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":21,"alternative-id":["S1201971223000899"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2023.03.013","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update of drug-resistant tuberculosis treatment guidelines: A turning point","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2023.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}